Current treatment options for acanthosis nigricans

Patel, Niketa A.; Roach, Catherine; Alinia, Hossein; Huang, William W.; Feldman, Steven R.

doi:10.2147/ccid.s137527

Cited by 50 publications

(50 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A trial with 40 patients having AN and IR with 500 mg metformin thrice daily for 3 months showed significant improvement in AN lesions of neck and axilla. 20 placebo‐controlled patients failed to show similar improvement 47 . An adolescent boy with normal weight having AN and IR showed complete clearance after eight years on metformin, 74 while another boy with IR and extensive AN had clearance of AN with persistent IR after two years on metformin 75 …”

Section: Systemic Treatmentsmentioning

confidence: 99%

“…Treatment of AN should always be aimed at correcting the underlying disease pathology 47 . There is no consensus on the best treatment.…”

Section: Treatmentmentioning

confidence: 99%

“…In drug‐induced AN, stopping the offending drug and switching to an alternative medication leads to resolution 47 …”

Section: Treatmentmentioning

confidence: 99%

“…However, we propose the application of modified Kligman triple combination formula, on account of the cutaneous side effects (atrophy, striae, addiction, dyspigmentation etc) of original Kligman formula. The modified triple combination regime (tretinoin 0.05%, hydroquinone 4%, fluocinolone acetonide 0.01%) at night has reportedly helped improving the lesions 47 . Besides, kojic acid alone or in combination with other molecules can be used as depigmenting agents.…”

Section: Topical Treatmentsmentioning

confidence: 99%

See 3 more Smart Citations

Acanthosis nigricans: A review

Das

Datta²,

Kassir

et al. 2020

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background Acanthosis nigricans (AN) is a cutaneous disorder characterized by symmetric velvety hyperpigmented plaques on intertriginous areas like axilla, neck, inframammary, and groin. Aims To summarize the pathophysiology and classification of AN, provide an update of diagnostic testing strategies, and describe the current therapeutic options described so far in the literature for this disease. Methods A comprehensive english language literature search across multiple databases (PubMed, EMBASE, MEDLINE, and Cochrane) for keywords (alone and in combination) was performed. MeSH as well as non‐MeSH terms such as “acanthosis nigricans,” “classification,” “pathophysiology,” “diagnosis,” “treatment,” “topical drugs,” “systemic drugs,” “chemical peeling,” and “lasers” were taken into consideration. Results The pathophysiology of AN revolves around a multifactorial stimulation of proliferation of epidermal keratinocytes and dermal fibroblasts. Various types of AN include benign, obesity‐associated, syndromic, malignant, acral, unilateral, medication‐induced, and mixed‐type. Homeostasis model assessment‐insulin resistance (HOMA‐IR) is a good tool for assessment of insulin resistance. Management involves general measures (weight reduction and addressing the underlying cause, if any), topical drugs (retinoids, vitamin D analogs, and keratolytics), oral drugs (retinoids and insulin sensitizers), chemical peels (trichloroacetic acid), and lasers (Long pulsed alexandrite, fractional 1550‐nm erbium fiber, and CO2). Conclusion Acanthosis nigricans is a treatable condition; however, complete cure and disappearance of lesions are difficult to achieve. Weight reduction is the most scientific and practical management strategy. Long‐term studies and further research is warranted in the pathophysiology and treatment of this common condition.

show abstract

Section: Systemic Treatmentsmentioning

confidence: 99%

“…Treatment of AN should always be aimed at correcting the underlying disease pathology 47 . There is no consensus on the best treatment.…”

Section: Treatmentmentioning

confidence: 99%

“…In drug‐induced AN, stopping the offending drug and switching to an alternative medication leads to resolution 47 …”

Section: Treatmentmentioning

confidence: 99%

Section: Topical Treatmentsmentioning

confidence: 99%

See 2 more Smart Citations

Acanthosis nigricans: A review

Das

Datta²,

Kassir

et al. 2020

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…keratinocytes and promote cell differentiation. 5,6 After 2 months of therapy, we saw a marked improvement in skin lesions, especially in the neck and axillae (Figures 2 and 3). The patient reduced her body weight, regained a regular menstrual cycle, and her mood tone improved as well as her quality of life.…”

mentioning

confidence: 92%

Acanthosis nigricans monstre successfully treated with topical tacalcitol, metformin, and oral contraceptives

Rizzo

Tognetti

Rubegni

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Acanthosis nigricans (AN) is a skin condition characterized by hyperpigmented and hyperkeratotic plaques with a velvety surface which are usually symmetrically distributed to the skin folds. 1,2 Recently, seven types of AN have been recognized: AN associated with metabolic, genetic, or autoimmune disorders, paraneoplastic AN, iatrogenic AN, idiopathic AN, and mixed-type AN. 2 The most common form of AN is associated with metabolic disorders like insulin resistance, diabetes mellitus, and obesity. The role of insulin resistance in the pathogenesis of AN is well defined. The high-insulin levels bind insulin-like growth factor 1 (IGF-1) receptors on keratinocytes and fibroblasts causing a proliferation of both with the development of hyperkeratotic plaques. 3 Two syndromes associated with insulin disorder have been described. Type A called HAIR AN is characterized by hyperandrogenemia, insulin resistance, and AN. Type B is associated with diabetes mellitus and ovarian hyperandrogenemia. 2 We present a case of a 34-year-old woman of Peruvian origin with AN of the neck, axillae, inframammary folds, abdomen, groin, and pubic region, associated with significant weight gain (33 kg in 1 year), amenorrhea, and depressive syndrome. Hirsutism and facies lunaris were also present (Figure 1). In order to exclude an underlying endocrinopathy or neoplasia, we performed an oral glucose tolerance test, which showed severe insulin resistance, a dosage of sex hormones (follicle stimolating hormone, luteinizing hormone, estradiol, progesterone, dehydroepiandrosterone, sex hormone binding globulin,

show abstract